Thermo Fisher Scientific Inc. (TMO) — ESG & Values Scores

Environment story

The 10-K discloses no quantitative Scope 1, 2, or 3 emissions data and no explicit net-zero target year, resulting in deductions for undisclosed Scope 3 trajectory and an absent/late net-zero commitment. Restructuring disclosures reference 'charges for environmental-related matters,' indicating some level of remediation or compliance activity, but severity/location details are not specified in the filing. No verified physical decarbonization capital projects (e.g., on-site renewable generation, electrification of manufacturing) are quantified in the provided documents, so no credit was given for infrastructure investment. This assessment is informational only and does not constitute financial advice.

Criticisms on file

10-K restructuring disclosures reference unspecified 'charges for environmental-related matters' within restructuring and other costs for 2024/2025, without further detail on nature, location, or magnitude.
Source: TMO_10k.txt - MD&A, Non-GAAP Measures footnote (c)

Disclosed initiatives

Practical Process Improvement (PPI) Business System

Internal continuous-improvement methodology cited as driving cost efficiencies, global sourcing initiatives, and lower-cost-region manufacturing; not explicitly framed as an environmental/decarbonization program in the filing.

Social story

The proxy references a CEO pay ratio disclosure section and a formal succession-planning process but does not include the actual numeric pay ratio, worker turnover rate, or supply-chain labor-audit findings within the provided text, so no penalty was applied for pay-ratio thresholds pending verified figures. Board nominee slate includes multiple women (at least five of eleven identified nominees), suggesting board-level gender representation above the 30% threshold referenced in the rubric; however, executive-leadership-team diversity percentages are not disclosed in the source material. No documented union-suppression activity, strikes, or supply-chain human-rights violations appear in the provided filings. This assessment is informational only and does not constitute financial advice.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

CEO and senior leadership succession planning

Board conducts formal annual succession-planning review for CEO, CFO, and other key leaders, including active mentoring of identified senior leaders.

Governance story

Thermo Fisher maintains a single-class common share structure (no dual-class supermajority voting identified), and the board includes an independent Lead Director (Scott Sperling) alongside a combined Chairman/CEO role held by Marc N. Casper. Board independence percentage is not explicitly quantified in the provided proxy excerpt, though the composition (10 of 11 nominees appear to be non-employee directors) suggests independence above the 75% threshold referenced in the rubric. Political spending oversight is delegated to the independent Nominating & Corporate Governance Committee, with stated commitment to transparent disclosure of contributions; specific annual lobbying dollar figures and any deregulation-focused advocacy are not disclosed in the source text. No active antitrust, consumer-safety, or financial-fraud regulatory proceedings are described beyond routine tax audits and product-liability litigation matters referenced in risk factors. This assessment is informational only and does not constitute financial advice.

Criticisms on file

Unrecognized tax benefit liability of $0.42B and prior-year tax audit provisions ($176M expense in 2024) reflect ongoing tax authority disputes across multiple jurisdictions.
Source: TMO_10k.txt - MD&A, Income Taxes section

Disclosed initiatives

Independent Lead Director structure

Independent directors annually elect a Lead Director (Scott Sperling) to provide independent oversight given the combined Chairman/CEO role.
Political spending oversight

N&CG Committee, composed solely of independent directors, oversees political and lobbying spending; company publishes an annual Political Contributions report.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Thermo Fisher Scientific Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Thermo Fisher Scientific Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Abbott Laboratories (ABT)